Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap
Status:
Completed
Trial end date:
2016-05-04
Target enrollment:
Participant gender:
Summary
The study is performed to assess the efficacy and safety of different doses of BAY1002670 in
subjects with uterine fibroids. The dose-response relationship will be evaluated. Further,
the study aims to establish a population pharmacokinetic/pharmacodynamic relationship for
BAY1002670 in subjects with uterine fibroids. To assess the efficacy of BAY1002670 the
interchangeability of menstrual pictogram and alkaline hematin method for the judgement of
menstrual blood loss will be assessed.